[1] Perls M.  Beiträge zur Geschwulstlehre[J]. Archiv Pathol Anat, 1872, 56(4): 437-467.   doi: 10.1007/BF01973432
[2]

Konstantinidis L, Damato B. Intraocular Metastases—A Review[J/OL]. Asia Pac J Ophthalmol, 2017, 6(2): 208−214[2019-03-31]. https://journals.lww.com/apjoo/Fulltext/2017/03000/Intraocular_Metastases_A_Review.12.aspx. DOI: 10.22608/APO.201712.
[3] Mathis T, Jardel P, Loria O, et al.  New concepts in the diagnosis and management of choroidal metastases[J]. Prog Retin Eye Res, 2019, 68: 144-176.   doi: 10.1016/j.preteyeres.2018.09.003
[4]

Bornfeld N, Biewald E, Bauer S, et al. The Interdisciplinary Diagnosis and Treatment of Intraocular Tumors[J/OL]. Dtsch Arztebl Int, 2018, 115(7): 106−111[2019-03-31]. https://www.aerzteblatt.de/int/archive/article/196273. DOI: 10.3238/arztebl.2018.0106.
[5] Arepalli S, Kaliki S, Shields CL.  Choroidal metastases: Origin, features, and therapy[J]. Indian J Ophthalmol, 2015, 63(2): 122-127.   doi: 10.4103/0301-4738.154380
[6] 丛春霞, 林锦镛, 王兰惠.  葡萄膜转移癌的临床病理学观察[J]. 中华眼科杂志, 2016, 52(10): 769-774.   doi: 10.3760/cma.j.issn.0412-4081.2016.010.010
Cong CX, Lin JY, Wang LH.  Clinical and pathologic observation of uveal metastatic carcinoma[J]. Chin J Ophthalmol, 2016, 52(10): 769-774.   doi: 10.3760/cma.j.issn.0412-4081.2016.010.010
[7] 郑惠, 董东升.  脉络膜转移癌的临床诊断及鉴别分析[J]. 现代肿瘤医学, 2016, 24(20): 3202-3205.   doi: 10.3969/j.issn.1672-4992.2016.20.008
Zheng H, Dong DS.  Clinical diagnosis and identification of metastatic tumor of the choroid[J]. J Med Oncol, 2016, 24(20): 3202-3205.   doi: 10.3969/j.issn.1672-4992.2016.20.008
[8] Papastefanou VP, Islam S, Szyszko T, et al.  Metabolic activity of primary uveal melanoma on PET/CT scan and its relationship with monosomy 3 and other prognostic factors[J]. Br J Ophthalmol, 2014, 98(12): 1659-1665.   doi: 10.1136/bjophthalmol-2014-305304
[9] Hübnr KF, Buonocore E, Gould HR, et al.  Differentiating Benign from Malignant Lung Lesions Using "Quantitative" Parameters of FDG PET Images[J]. Clin Nucl Med, 1996, 21(12): 941-949.   doi: 10.1097/00003072-199612000-00005
[10] 葛冉, 赵丽霞, 田蓉, 等.  18F-FDG PET-CT在寻找转移瘤原发灶中的临床价值[J]. 中国临床医学影像杂志, 2012, 23(10): 722-726.   doi: 10.3969/j.issn.1008-1062.2012.10.011
Ge R, Zhao LX, Tian R, et al.  The role of 18F-FDG PET-CT in the detection of primary lesions for patients with tumor metastasis[J]. J Chin Clin Med Imaging, 2012, 23(10): 722-726.   doi: 10.3969/j.issn.1008-1062.2012.10.011
[11] Kwee TC, Kwee RM.  Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis[J]. Eur Radiol, 2009, 19(3): 731-744.   doi: 10.1007/s00330-008-1194-4
[12] Patel P, Finger PT.  Whole-Body 18F FDG Positron Emission Tomography/Computed Tomography Evaluation of Patients With Uveal Metastasis[J]. Am J Ophthalmol, 2012, 153(4): 661-668.   doi: 10.1016/j.ajo.2011.09.028
[13] 张毓艺, 姚稚明, 陈聪霞, 等.  FDG PET/CT原发性代谢对非小细胞肺癌区域淋巴结转移预测价值[J]. 中华肿瘤防治杂志, 2018, 25(11): 816-820.   doi: 10.16073/j.cnki.cjcpt.2018.11.013
Zhang YY, Yao ZM, Chen CX, et al.  Value of metabolism by using FDG PET/CT of NSCLC primary tumor in prediction of lymph node metastasis[J]. Chin J Cancer Prev Treat, 2018, 25(11): 816-820.   doi: 10.16073/j.cnki.cjcpt.2018.11.013
[14] Orsaria P, Chiaravalloti A, Caredda E, et al.  Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer[J]. Anticancer Res, 2018, 38(12): 6639-6652.   doi: 10.21873/anticanres.13031
[15] Ho KC, Toh CH, Li SH, et al.  Prognostic impact of combining whole-body PET/CT and brain PET/MR in patients with lung adenocarcinoma and brain metastases[J]. Eur J Nucl Med Mol Imaging, 2019, 46(2): 467-477.   doi: 10.1007/s00259-018-4210-1